Neoral Oral Solution ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
269化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群2

269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群


臨床試験数 : 23 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 106
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-008291-14-IE
(EUCTR)
31/03/201008/10/2009Study of treatments in Pyoderma Gangrenosum patients - STOP GAPStudy of treatments in Pyoderma Gangrenosum patients - STOP GAP pyoderma gangrenosum
MedDRA version: 9.1;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum
MedDRA version: 9.1;Classification code 10037635;Term: Pyoderma gangrenosum
Trade Name: Neoral soft gelatin capsules
INN or Proposed INN: CICLOSPORIN
Trade Name: Neoral Oral Solution
INN or Proposed INN: CICLOSPORIN
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Nottingham University Hospitals NHS TrustNULLNot RecruitingFemale: yes
Male: yes
Ireland;United Kingdom
2EUCTR2008-008291-14-GB
(EUCTR)
14/05/200922/05/2009Study of treatments in Pyoderma Gangrenosum patients - STOP GAPStudy of treatments in Pyoderma Gangrenosum patients - STOP GAP pyoderma gangrenosum
MedDRA version: 14.0;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
MedDRA version: 14.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
Trade Name: Neoral soft gelatin capsules
INN or Proposed INN: CICLOSPORIN
Trade Name: Neoral Oral Solution
INN or Proposed INN: CICLOSPORIN
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Nottingham University Hospitals NHS TrustNULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesIreland;United Kingdom